347 results about "Hypromellose" patented technology

The invention relates to the technical field of medicines, in particular to a sustained-release coating as well as a preparation method and application thereof. The coating adopts a three-layer gradient structure design and comprises an inner layer coating, a middle layer coating and an outer layer coating, and the layers are compounded and matched through ethyl cellulose and hydroxypropyl methylcellulose with different molecular weights and are combined with talcum powder filling amount with gradient decreasing and a triethyl citrate plasticizer, so that accurate regulation and control of drug release are realized. Through hierarchical swelling-diffusion dynamic balance, burst release is inhibited, the inner layer has high talcum powder content to resist initial swelling stress, the outer layer has low filling amount to maintain hydrophobic continuity, interface defects are reduced in combination with high-temperature curing, and the release stability and long-term storage performance of drugs such as dihydroergoline mesylate are remarkably improved; the problems of sudden release, damp-heat sensitivity, impurity generation and the like of a traditional single-layer coating are solved.

The invention relates to a sustained-release tablet capable of avoiding sudden release of a medicine after being taken together with an alcoholic beverage, the sustained-release tablet comprises a sustained-release tablet core and an anti-sudden-release material coating layer wrapping the sustained-release tablet core, and the anti-sudden-release material is composed of a polysaccharide substance and a cellulose derivative, the polysaccharide substance is selected from one or more of guar gum, xanthan gum and Arabic gum, the cellulose derivative is selected from one or more of hydroxypropyl methylcellulose, ethyl cellulose and hydroxyethyl cellulose, and the weight ratio of the polysaccharide substance to the cellulose derivative is 1: 1-10: 1. The sustained-release tablet disclosed by the invention has an excellent burst release resisting effect when being taken together with an alcoholic beverage, and the clinical medication safety and effectiveness of a preparation are improved.

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The invention belongs to the field of new materials, and particularly discloses a high-dispersity high-specific-surface-area calcium hydroxide preparation process which comprises the following steps: S1, adjusting an additive and deionized water to prepare a digestion mixed solution; the additive is hydroxypropyl methylcellulose and methacrylic acid, and ultrasonic treatment is carried out in the mixing process; s2, the quick lime and the digestion mixed solution enter a digestion machine to be subjected to a digestion reaction, and calcium hydroxide slurry is obtained; s3, the calcium hydroxide slurry passes through an aging barrel, aging is conducted for 12-36 h under stirring, and the obtained refined calcium hydroxide slurry is pressed into a filter cake through a filter press; s4, primarily powdering the filter cake, drying, scattering into powder, and packaging to obtain calcium hydroxide with high dispersity and high specific surface area; according to the method, the existing quick lime raw material is used, the hydroxypropyl methylcellulose and the methacrylic acid are used as additives, the calcium hydroxide prepared after digestion and aging has the high specific surface area of 45 m < 2 > / mL or above, the raw materials are easy to obtain, the preparation condition is mild, the preparation cost is low, and the method is suitable for large-scale industrial production.

The present invention provides a betahistine antioxidant tablet and a preparation method thereof, the betahistine antioxidant tablet comprises: a first zone comprising anhydrous citric acid, microcrystalline cellulose and hydroxypropyl methylcellulose; the middle buffer area is a sodium alginate aqueous solution coating; a second zone including calcium carbonate, betahistine, and microcrystalline cellulose; the first zone is located at the top of the tablet, the second zone is located at the bottom, and the buffer zone physically isolates the first zone from the second zone. The first zone, the buffer zone and the second zone are designed to form a sandwich structure, oxidation resistance is realized through dual mechanisms of physical isolation and chemical neutralization, and CO2 generated by reaction of food-grade citric acid and calcium carbonate is used for physically replacing oxygen.

The invention provides an additive composition for promoting itraconazole absorption, and the additive composition is prepared from the following components in parts by mass: 20 to 40 parts of modified hydroxypropyl methylcellulose acetic acid succinate, 10 to 25 parts of copovidone, 5 to 15 parts of N-capryloyl sodium salicylate, 2 to 8 parts of nano silicon dioxide and 3 to 10 parts of polyoxyethylene-polyoxypropylene segmented copolymer. According to the additive composition disclosed by the invention, the problems of dissolution rate, bioavailability and stability of the itraconazole oral preparation are comprehensively solved through polymer modification, compounding synergy and parameter optimization, and the process cost is remarkably lower than that of the prior art.

The invention relates to the field of pharmacy, and discloses a felodipine sustained release tablet and a preparation method thereof.The felodipine sustained release tablet comprises a tablet core and a film coating layer wrapped outside the tablet core, and the tablet core comprises the following components in parts by mass: 3.5-5.0 parts of felodipine nanocrystals; 50 to 65 parts of modified hydroxypropyl methylcellulose; the preparation method comprises the following steps: S1, preparing felodipine nanocrystals: dissolving felodipine in an organic solvent, and carrying out anti-solvent precipitation and high-pressure homogenization treatment, so as to obtain a nanocrystal suspension; drug nanocrystals are embedded between silicate layers through an ultrasonic embedding technology, and burst release is inhibited by combining physical confinement and electrostatic adsorption; the gradient pore skeleton constructs a pore layer-by-layer decreasing structure through fluidized bed multi-temperature zone deposition, the release rate is accurately regulated and controlled, and collapse is avoided; the ionic liquid stabilizer is introduced, and the problems of nanocrystal aggregation and degradation are synchronously solved through hydrogen bond anchoring and an antioxidant function.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral instant film with high drug loading capacity. The oral instant film agent comprises the following components: an active component, a film-forming material, a plasticizer, a coloring agent and a flavoring agent. The film-forming material is preferably combined with hydroxypropyl methylcellulose E15 and xanthan gum, so that the high drug loading capacity of the oral cavity instant film agent is ensured. Film-forming materials including hydroxypropyl methylcellulose E15 and xanthan gum are combined and compounded with a plasticizer polyethylene glycol 400, and sucralose is adopted as a flavoring agent, so that the stability of the oral instant film agent is ensured. The oral cavity instant film is good in appearance property, moderate in flexibility, good in taste, high in drug loading capacity, good in stability, low in cost, easy to operate, free of heating and suitable for industrial production.

The invention discloses a headspace gas chromatography detection method for simultaneously determining multiple residual solvents in pharmaceutical adjuvant hydroxypropyl methylcellulose. The headspace gas chromatography detection method comprises the following steps: preparing a reference solution containing the residual solvents; preparing a test solution of hydroxypropyl methylcellulose; respectively injecting the reference solution and the test solution into a headspace gas chromatograph for testing, and calculating the content of each residual solvent by peak area according to an external standard method; through accurate control of gas chromatography conditions, the method can accurately, rapidly and simultaneously detect the contents of residual methanol, isopropanol, dichloromethane, trichloromethane, benzene, trichloroethylene, dioxane and toluene in the pharmaceutical adjuvant hydroxypropyl methylcellulose, and has the advantages of simplicity and convenience in operation, high accuracy and sensitivity, good reproducibility and the like.

The invention relates to the technical field of oral solid preparations, in particular to a high-bioavailability coenzyme Q10 tablet and a preparation method thereof. The coenzyme Q10 tablet comprises an active component coenzyme Q10, a filler, an adhesive, a disintegrating agent, a lubricant and a high polymer material, compared with the prior art, hydroxyethyl methylcellulose and hydroxypropyl methylcellulose succinate are mixed according to a certain mass ratio to serve as a high polymer carrier material, the prepared coenzyme Q10 tablet can be rapidly dissolved out in vitro, and the coenzyme Q10 tablet has the advantages that the preparation process is simple, and the cost is low. Moreover, the stability of the medicine can be improved, the medicine can be rapidly absorbed in vivo after being orally taken, the oral bioavailability of the coenzyme Q10 is greatly improved, and a preparation process of the preparation is simple to operate, good in reproducibility and suitable for industrial production.

The invention provides a tandospirone citrate film-coated tablet and a preparation method thereof.The film-coated tablet comprises a tablet core and a coating, and the tablet core is prepared from tandospirone citrate, pregelatinized starch, corn starch, calcium carboxymethyl cellulose, polyvinyl alcohol EG-05P and magnesium stearate; according to the present invention, the coating powder comprising hydroxypropyl methylcellulose, concentrated glycerol, titanium dioxide and carnauba wax is adopted to coat the obtained tablet core, the use amount of each component and the coating weight gain ratio are controlled, the hygroscopicity of the tandospirone citrate is covered, and the fluidized bed granulation mode is adopted to substantially reduce the batch-to-batch difference, and simultaneously control the particle size of the bulk drug, according to the present invention, the dissolution rate of the sample can be always maintained within a certain range, and the dissolution RSD in the phosphate medium with the pH value of 6.8 for 5 min is far less than the dissolution RSD in the original development agent, such that the intra-batch uniformity is ensured, and the problems of non-uniform granulation, large inter-batch difference, and lactose intolerance due to the long-term use of lactose during the preparation process are solved.

The present invention relates to an ophthalmic preparation. The ophthalmic preparation comprises: penehyclidine hydrochloride, phosphate buffer, sodium chloride and hypromellose; wherein, based on the total volume of the ophthalmic preparation, the concentration of the phosphate buffer is not higher than 25 mM and not 0 mM, the mass-volume ratio of penehyclidine hydrochloride is 0.01% - 2%, and the mass ratio of penehyclidine hydrochloride to sodium chloride is (0.011 - 0.85):1. The ophthalmic preparation of the present invention has the advantages of low irritation and high stability.

The invention provides a pharmaceutical composition containing fenerenone, which comprises the following components in percentage by weight: 1.0%-30.0% of fenerenone, 1.0%-5.0% of hydroxypropyl methylcellulose, 0.1%-1.0% of lauryl sodium sulfate, 5.0%-15.0% of polyvinylpolypyrrolidone and 0.5%-5.0% of sodium stearyl fumarate. The filler is microcrystalline cellulose and lactose monohydrate, a wet granulation process is adopted, the pharmaceutical composition has the characteristics of stable and rapid dissolution and rapid disintegration of the fenerenone, the process is simple, the production steps are simplified, the production efficiency is improved, and the cost is reduced.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to nitrogen hydrochloride # imgabs0 # stine eye drops and a preparation process thereof, the nitrogen hydrochloride # imgabs0 # stine eye drops comprise 0.05% of nitrogen hydrochloride # imgabs1 # stine, 0.2-0.3% of hydroxypropyl methylcellulose, 0.1-0.2% of edetate disodium, 0.12-0.15% of an isoosmotic adjusting agent, 0.04-0.07% of a preservative and 0.005-0.0075% of choline aromatic folic acid; the nitrogen hydrochloride # imgabs2 # stine eye drops prepared by the preparation method disclosed by the invention have the advantages that the adsorption of nitrogen hydrochloride # imgabs3 # stine on a low-density polyethylene bottle is well inhibited under the condition of visible light, and the reduction of the concentration of nitrogen hydrochloride # imgabs4 # stine in the eye drops is remarkably prevented, so that the medication safety is improved. Besides, the added cholinofolic acid and hydroxypropyl methylcellulose have small irritation to eyes under a specific ratio, and can also have a large enough contact angle with the eyes of rabbits at high temperature, so that the retention property of the eye drops on the eyes can be improved, and the drug effect can be favorably exerted.

The invention relates to the field of pharmaceutical preparations, in particular to water-free swallowing granules and a preparation method thereof. The water-free swallowing granules provided by the invention comprise drug-containing taste-masking granules and a taste-modifying material, and the drug-containing taste-masking granules are prepared from drug-containing pellets and the taste-masking material; the raw material of the drug-containing pellet comprises an adhesive, and the adhesive is selected from one or more of povidone, hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl cellulose or starch slurry; the weight ratio of the drug-containing pellet to the taste masking material is (2-10): 1; the taste masking material comprises a coating component and an anti-sticking agent, wherein the coating component is selected from one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methyl cellulose phthalate and carboxymethyl ethyl cellulose; the anti-sticking agent is selected from one or two of lauryl sodium sulfate and talcum powder, and the obtained water-free swallowing granules are easy to swallow and good in stability.

The invention provides an apattamide solid dispersion as well as a preparation method and application thereof. The apattamide solid dispersion comprises apattamide and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in a mass ratio of 1: (3.0-3.5). The D90 particle size of the solid dispersion is 60-90 [mu] m, and the D50 particle size of the solid dispersion is 30-45 [mu] m. According to the dispersoid, by adjusting the ratio of the apattamide to the HPMCAS and selecting a proper particle size range, a preparation which can be dissolved out well is obtained. Experimental results show that the D90 particle size of the solid dispersion is 61-87 [mu] m, the D50 particle size is 30-43 [mu] m, the 60 min dissolution rate in SDS with the pH value of 4.5 + 0.2% is 90% or above, meanwhile, the similarity of a dissolution curve and a commercially available product is high, and the relatively close in-vivo absorption speed and degree are predicted.

The present invention relates to the technical field of eye drops, and specifically discloses a kind of wetting boric acid eye drops. The present invention also discloses a preparation method of the above-mentioned wetting boric acid eye drops, boric acid, chlorhexidine gluconate solution, and calcium disodium edetate are added to water, and stirred at 60-70°C to obtain a boric acid complex; sodium hyaluronate and sodium alginate are added to water and stirred, and hypromellose is added, and stirred at 30-40°C to obtain a hypromellose complex; soy lecithin, cholesterol, and ethylparaben are added to chloroform and stirred to obtain phase A; collagen and carboxymethyl chitosan are added to citric acid aqueous solution and stirred to obtain phase B; phase A is added to phase B under stirring, ultrasonic treatment, 50-60°C vacuum rotary evaporation to remove chloroform, citric acid aqueous solution is added for hydration, ultrasonic treatment, and filtration to obtain liposomes; boric acid complex, hypromellose complex, and liposomes are mixed evenly, and the pH value of the adjustment system is 6.5-7.5.

The invention relates to the technical field of empty capsules, in particular to a production process of enteric plant empty capsules. The preparation method comprises the following steps: firstly, taking hydroxypropyl methylcellulose as a main material, taking carrageenan, Tween 80 and sodium alginate as auxiliary materials, mixing the main material, the auxiliary materials and water, and carrying out glue dipping, forming, drying, demolding and cutting processes to obtain an empty capsule; the preparation method comprises the following steps: modifying chitosan by adopting sodium palmitate, so as to obtain chitosan-palmitate with hydrophobic property; and mixing the chitosan-palmitate with the hydroxypropyl methylcellulose acetate succinate to prepare a coating solution, and coating the hollow capsule to obtain a finished product. The prepared enteric plant empty capsule is high in yield, low in moisture absorption rate and long in disintegration time in gastric acid, it is ensured that effective components are released on the upper portion of the small intestine, and the absorption efficiency is improved.

The invention relates to the technical field of pet medicine research and development, and particularly discloses an emotion relieving capsule preparation method based on a composite formula, the method comprises the following steps: mixing lavender extract and gamma-cyclodextrin to obtain embedding modified micro powder, carrying out enzymolysis on L-theanine to prepare powder, cross-linking gamma-aminobutyric acid and sodium alginate to obtain a nano composite carrier, and carrying out freeze drying on the nano composite carrier to obtain the emotion relieving capsule based on the composite formula. Mixing the three components to prepare a slow-release composite base material, mixing the slow-release composite base material with vitamin B6 and the like, sieving, finally filling into a hydroxypropyl methylcellulose hollow capsule shell, and coating with a film to prepare the capsule. Parameters such as raw material proportion and reaction conditions are definitely limited in each step. According to the capsule, the emotion of pets is relieved through a compound formula and cooperation of multiple components, the preparation method is scientific and reasonable, the product quality is controllable, the emotion problem caused by factors such as environment and living habits of the pets can be effectively solved, and the capsule has good application prospects.

The invention discloses a sustained and controlled release hydroxypropyl methylcellulose hollow capsule, and relates to the technical field of capsules, in order to realize a long-term sustained and controlled release effect of a drug, a hard shell of the capsule is improved, and antibacterial modified polysaccharide is added into raw materials, so that the compactness and barrier property of the capsule shell after curing and drying are improved, and the sustained and controlled release effect of the drug is improved. The drug protection performance is improved; in addition, in consideration of the fact that part of medicine capsules can be stored in medicine bottles which are taken for multiple times, the guanidyl and chitosan structures added into the prepared hollow capsule shell can provide excellent antibacterial and anti-pollution capacity for the capsules, growth and pollution of infectious microbes are avoided, and the efficacy of the medicine is maintained for a long time.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a saxagliptin metformin sustained release tablet and a preparation method thereof. The saxagliptin and metformin sustained release tablet comprises a saxagliptin pellet, a metformin hydrochloride pellet and a color coating, the saxagliptin pellet is prepared from the following raw materials: saxagliptin monohydrate, a silicon dioxide pellet core, hydroxypropyl methylcellulose, talcum powder and hydrochloric acid, the metformin hydrochloride pellet is prepared from the following raw materials: metformin hydrochloride, ethyl cellulose and triethyl citrate; the color coating comprises the following raw materials: a gastric-soluble film coating premix, hydrochloric acid and polyethylene glycol. The medicine is stable in quality, accurate in dosage and short in production time, and the quality is consistent with that of an original developed preparation.

The invention discloses an L-carnitine composite tablet with high hygroscopicity resistance and a preparation method of the L-carnitine composite tablet. The preparation method comprises the following steps: S1, adding 65-80 parts by weight of dietary fiber, 1-3 parts by weight of tea polyphenol, 5-10 parts by weight of isomaltitol, 1-3 parts by weight of calcium carbonate and 0.75-1.5 parts by weight of hydroxypropyl methylcellulose into a boiling drying granulator, and mixing to obtain mixed powder; s2, uniformly spraying a citric acid solution on the surface of the mixed powder in a guniting manner to obtain a first guniting material; s3, uniformly spraying an L-carnitine solution on the surface of the first guniting material in a guniting manner, so that L-carnitine is uniformly absorbed in pores of dietary fibers and honeycomb-shaped pores generated by citric acid and calcium carbonate to obtain a second guniting material; and S4, carrying out guniting granulation by utilizing 0.25-0.5 part of a hydroxypropyl methylcellulose solution, adding 2-3 parts by weight of a lubricant and an anti-caking agent after granulation is completed, uniformly mixing to obtain a total mixed material, tabletting, and coating to obtain the L-carnitine composite tablet.

The invention provides a dexketoprofen trometamol oral solution and a preparation method thereof. According to the dexketoprofen trometamol oral solution, polyethylene glycol 400 and hydroxypropyl methylcellulose are used as stabilizing agents, methylparaben and propyl hydroxybenzoate are used as bacteriostatic agents, sucralose and ammonium glycyrrhizinate are used as sweetening agents, essence is used as a flavoring agent, and the pH value of the solution is controlled to be 6.2-6.8 through a pH value regulator. The increase of the impurity A, the impurity B, the impurity C, the impurity E and the total impurity is obviously reduced, so that the product stability is obviously improved.

The invention discloses a preparation process of a hydroxypropyl methylcellulose hollow hard capsule, and relates to the technical field of hydroxypropyl methylcellulose hollow hard capsules, the preparation process comprises the following steps: adding mixed hydroxypropyl starch, potassium citrate and modified chitosan into ultrapure water, heating, stirring and dissolving to obtain a glue solution; the preparation method comprises the following steps: sequentially adding hydroxypropyl methyl cellulose, carrageenan, succinic acid and a plasticizer into a glue solution, uniformly stirring, adding gallic acid, stirring at room temperature for 10-15 minutes, adding alkyl dialdehyde, stirring at room temperature in a dark place for 2 hours, removing bubbles, preserving heat for 2-4 hours, dipping glue and preparing a capsule, thereby obtaining the hydroxypropyl methyl cellulose hollow hard glue.

The invention relates to the technical field of pharmaceutical preparations, in particular to a fluconazole dry suspension and a preparation method thereof. The fluconazole dry suspension composition comprises the following components in parts by weight: 160 parts of fluconazole, 2100-2300 parts of a filler, 27-35 parts of a suspending aid, 2-6 parts of a lubricant and a proper amount of a pH regulator, the suspending aid is a composition of hydroxypropyl methylcellulose and glucan, and the mass ratio of the hydroxypropyl methylcellulose to the glucan is (2: 1)-(4: 1); the amount of the pH regulator enables the pH of the suspension containing 40mg of fluconazole per 1mL prepared by adding water into the dry suspension to be 3.0-4.5. The fluconazole dry suspension disclosed by the invention is slow in sedimentation in water, good in suspension property, free from caking after sedimentation and capable of being quickly redispersed after being shaken, and the prepared fluconazole dry suspension is good in flowability and good in uniformity.

The invention provides a sodium valproate sustained release tablet with a stable crystal form and a preparation method of the sodium valproate sustained release tablet, and relates to the technical field of pharmacy. The preparation method comprises the following steps: dissolving sodium valproate, valproic acid and ethyl cellulose in a solvent to prepare a medicine solution; putting hydroxypropyl methylcellulose and silicon dioxide into a fluidized bed, controlling the air inlet volume, the air inlet temperature and the atomization pressure, spraying the medicine solution into a fluidization chamber, maintaining the material temperature to be stable, granulating, finishing granules, adding saccharin sodium salt and colloidal silicon dioxide, and totally mixing; tabletting to obtain a tablet core; and controlling the temperature of the tablet bed, and coating the tablet core to prepare the sodium valproate sustained-release tablet. The preparation process is simple, the sodium valproate and the valproic acid can be fully contacted to form a complete solvate, the obtained preparation is consistent in crystal form between batches, the crystal form is stable in the storage process, and the medicine can be continuously and stably released within 24 hours.

The disclosed composition consists of 15 mg Ferula asafetida (Hing) oil as an active ingredient, 85 mg Frankincense oil and 400 mg coconut oil as in-active ingredients in an enteric coated HPMC capsule form. The process of preparation consists of steps of blending asafetida (hing) oil with Frankincense oil and coconut oil followed by dispensing the blended oils into empty HPMC capsule shell, which are automatically filled in liquid filling machine. Further a banding solution containing 0.025 ml HPMC (surfactant), 2.8 mg IPA (Binding Agent) and 0.03 mg Chocolate brown color (colorant) are filled into the bath of band sealing machine at room temperature where the hing oil containing capsules are band sealed. The disclosed oral formulation in the form of HPMC capsule is natural, low cost, highly efficacious and quick in management primary dysmenorrhea.

The invention belongs to the technical field of cosmetics, and particularly relates to a mask formula and a processing method thereof, the mask formula takes natural active ingredients as a core, and multiple skin care advantages are realized through scientific proportioning and an innovative process. A film forming system adopts a sodium alginate and hydroxypropyl methylcellulose compounding technology to form an air-permeable film, so that the air-permeable film can be tightly attached to the skin to promote absorption, and the skin stuffiness feeling of a traditional mask is avoided; cold-pressed camellia-seed oil is selected as a matrix, high-content oleic acid of the cold-pressed camellia-seed oil is highly matched with a sebum structure, and a bionic lipid barrier is formed by matching with ceramide, so that the water locking and repairing capability is remarkably improved. Microencapsulated nicotinamide and concentrated portulaca oleracea extract are creatively applied in an active system to achieve synergistic interaction, the microencapsulated nicotinamide continuously whitens skin and fades spots through a slow release technology, and the concentrated portulaca oleracea extract contains flavonoid compounds to accurately relieve inflammation and reduce sensitivity risks.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to emedastine fumarate eye drops and a preparation method thereof. The invention provides emedastine fumarate eye drops, the pH value of the emedastine fumarate eye drops is 7.2-7.6, and the emedastine fumarate eye drops are prepared from the following components in parts by weight: 0.84-0.92 part of emedastine fumarate, 2-3 parts of a thickening agent, 4.5-5.5 parts of a buffering agent, 6-8 parts of an osmotic pressure regulator, a pH regulator and 950-1050 parts of water, wherein the thickening agent is hydroxypropyl methylcellulose 2910. According to the emedastine fumarate eye drops disclosed by the invention, the hydroxypropyl methylcellulose 2910 is used as a thickening agent, so that the obtained emedastine fumarate eye drops are more clear, less in impurity content and higher in stability; meanwhile, a specific preparation method is limited, the dissolution time of the osmotic pressure regulator is greatly shortened, and the production efficiency is improved.

The invention provides a traditional Chinese medicine compound for preventing and treating metabolism-related fatty liver diseases, a capsule and application, and relates to the field of medicines. The traditional Chinese medicine compound is prepared from the following raw materials in parts by weight: 1-5 parts of a turmeric extract, 10-20 parts of a radix puerariae extract, 15-30 parts of a salvia miltiorrhiza extract, 1-10 parts of a schisandra chinensis extract and 2-15 parts of a lucid ganoderma extract. The preparation method of the capsule comprises the following steps: uniformly mixing the turmeric extract, the kudzuvine root extract, the salvia miltiorrhiza extract, the schisandra chinensis extract, the lucid ganoderma extract and the maltodextrin, and filling the mixture into a hydroxypropyl methylcellulose hollow capsule to obtain the capsule. Salvia miltiorrhiza is used as a monarch drug, turmeric and radix puerariae are used as ministerial drugs, and schisandra chinensis and lucid ganoderma are used as adjuvant drugs, so that the traditional Chinese medicine composition has the functions of protecting liver, promoting blood circulation and qi circulation, helping produce saliva and slake thirst, tonifying qi and soothing nerves and the like, can effectively prevent and treat metabolism-related fatty liver diseases, and can treat non-alcoholic fatty liver diseases; particularly, the traditional Chinese medicine composition has an obvious treatment effect on non-alcoholic simple fatty liver and non-alcoholic fatty liver hepatitis.